Upstream Bio, Inc. (NASDAQ:UPB) Stock Now Rated “Hold” by Sell-Side Analysts

Upstream Bio, Inc. (NASDAQ:UPB) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $29.67.

Several brokerages recently issued reports on UPB. Weiss Ratings raised shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. lifted their price target on shares of Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of Upstream Bio in a research note on Wednesday, September 2nd. Truist Financial dropped their price objective on shares of Upstream Bio to $25.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th.

Upstream Bio Stock Performance

Upstream Bio stock opened at $2.82 on Wednesday. Upstream Bio has a 52-week low of $2.74 and a 52-week high of $33.68. The stock’s 50 day moving average price is $5.56 and its two-hundred day moving average price is $7.07.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The company had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million. Analysts anticipate that Upstream Bio will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of Upstream Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Walleye Capital LLC acquired a new position in Upstream Bio during the 2nd quarter worth approximately $3,450,000. BlackRock Inc. acquired a new stake in Upstream Bio in the second quarter valued at approximately $25,973,000. Bank of America Corp DE acquired a new stake in Upstream Bio in the second quarter valued at approximately $2,711,000. Deutsche Bank AG acquired a new stake in Upstream Bio in the second quarter valued at approximately $1,671,000. Finally, Squarepoint Ops LLC grew its stake in Upstream Bio by 551.9% in the second quarter. Squarepoint Ops LLC now owns 290,904 shares of the company’s stock valued at $2,013,000 after acquiring an additional 246,278 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. The company’s research is centered on targeting biological pathways involved in immune-system activation and chronic inflammation, with an emphasis on conditions affecting the airways.

Upstream Bio’s lead product candidate is verekitug, formerly known as UPB-101. Verekitug is a long-acting monoclonal antibody designed to selectively inhibit thymic stromal lymphopoietin, or TSLP, a cytokine that contributes to the development and persistence of inflammation.